REGENXBIO Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
REGENXBIO Inc. (RGNX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $61.12 million as of 2019-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2021-03-01
- 2019-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $61.12M.
- 2019-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $61.12M.
- 2019-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $61.12M.
- 2019-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $61.12M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2019-12-31 | $61.12M 10-K · filed 2021-03-01 |
| 2019-09-30 | $61.12M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $61.12M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $61.12M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $310.83M 10-K · filed 2020-02-26 |
| 2018-03-31 | $155.38M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $126.36M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |